SEAMARK

Patients with both BRAF V600E mutations and microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) have poor prognosis. Currently, there are no specifically targeted first-line treatment options indicated for patients with mCRC whose tumors harbo...

Full description

Bibliographic Details
Authors: Elez, Elena|||0000-0002-4653-6324, Kopetz, Scott, Tabernero, Josep|||0000-0002-2495-8139, Bekaii-Saab, Tanios, Taieb, Julien|||0000-0002-9955-4753, Yoshino, Takayuki|||0000-0002-0489-4756, Manji, Gulam, Fernandez, Kathrine, Abbattista, Antonello, Zhang, Xiaosong, Morris, Van K
Format: article
Publication Date:2024
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:English
OAI Identifier:oai:ddd.uab.cat:326606
Online Access:https://ddd.uab.cat/record/326606
https://dx.doi.org/urn:doi:10.2217/fon-2022-1249
Access Level:Open access
Keyword:BRAF V600
Cetuximab
dMMR
Encorafenib
Immunotherapy
Metastatic colorectal cancer
MSI-H
Pembrolizumab
Targeted therapy
Triplet combination therapy
id ES_6ae5c3eed6035cc08efaeb2f6070fbfe
oai_identifier_str oai:ddd.uab.cat:326606
network_acronym_str ES
network_name_str España
repository_id_str
spelling SEAMARKphase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRCElez, Elena|||0000-0002-4653-6324Kopetz, ScottTabernero, Josep|||0000-0002-2495-8139Bekaii-Saab, TaniosTaieb, Julien|||0000-0002-9955-4753Yoshino, Takayuki|||0000-0002-0489-4756Manji, GulamFernandez, KathrineAbbattista, AntonelloZhang, XiaosongMorris, Van KBRAF V600CetuximabdMMREncorafenibImmunotherapyMetastatic colorectal cancerMSI-HPembrolizumabTargeted therapyTriplet combination therapyPatients with both BRAF V600E mutations and microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) have poor prognosis. Currently, there are no specifically targeted first-line treatment options indicated for patients with mCRC whose tumors harbor both molecular aberrations. Pembrolizumab is a checkpoint inhibitor approved for the treatment of MSI-H/dMMR mCRC, and the BRAF inhibitor encorafenib, in combination with cetuximab, is approved for previously treated BRAF V600E-mutant mCRC. Combination of pembrolizumab with encorafenib and cetuximab may synergistically enhance antitumor activity in patients with BRAF V600E-mutant, MSI-H/dMMR mCRC. SEAMARK is a randomized phase II study comparing the efficacy of the combination of pembrolizumab with encorafenib and cetuximab versus pembrolizumab alone in patients with previously untreated BRAF V600E-mutant, MSI-H/dMMR mCRC. 22024-01-0120242024-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/326606https://dx.doi.org/urn:doi:10.2217/fon-2022-1249reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3266062026-06-06T12:50:31Z
dc.title.none.fl_str_mv SEAMARK
phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC
title SEAMARK
spellingShingle SEAMARK
Elez, Elena|||0000-0002-4653-6324
BRAF V600
Cetuximab
dMMR
Encorafenib
Immunotherapy
Metastatic colorectal cancer
MSI-H
Pembrolizumab
Targeted therapy
Triplet combination therapy
title_short SEAMARK
title_full SEAMARK
title_fullStr SEAMARK
title_full_unstemmed SEAMARK
title_sort SEAMARK
dc.creator.none.fl_str_mv Elez, Elena|||0000-0002-4653-6324
Kopetz, Scott
Tabernero, Josep|||0000-0002-2495-8139
Bekaii-Saab, Tanios
Taieb, Julien|||0000-0002-9955-4753
Yoshino, Takayuki|||0000-0002-0489-4756
Manji, Gulam
Fernandez, Kathrine
Abbattista, Antonello
Zhang, Xiaosong
Morris, Van K
author Elez, Elena|||0000-0002-4653-6324
author_facet Elez, Elena|||0000-0002-4653-6324
Kopetz, Scott
Tabernero, Josep|||0000-0002-2495-8139
Bekaii-Saab, Tanios
Taieb, Julien|||0000-0002-9955-4753
Yoshino, Takayuki|||0000-0002-0489-4756
Manji, Gulam
Fernandez, Kathrine
Abbattista, Antonello
Zhang, Xiaosong
Morris, Van K
author_role author
author2 Kopetz, Scott
Tabernero, Josep|||0000-0002-2495-8139
Bekaii-Saab, Tanios
Taieb, Julien|||0000-0002-9955-4753
Yoshino, Takayuki|||0000-0002-0489-4756
Manji, Gulam
Fernandez, Kathrine
Abbattista, Antonello
Zhang, Xiaosong
Morris, Van K
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv BRAF V600
Cetuximab
dMMR
Encorafenib
Immunotherapy
Metastatic colorectal cancer
MSI-H
Pembrolizumab
Targeted therapy
Triplet combination therapy
topic BRAF V600
Cetuximab
dMMR
Encorafenib
Immunotherapy
Metastatic colorectal cancer
MSI-H
Pembrolizumab
Targeted therapy
Triplet combination therapy
description Patients with both BRAF V600E mutations and microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC) have poor prognosis. Currently, there are no specifically targeted first-line treatment options indicated for patients with mCRC whose tumors harbor both molecular aberrations. Pembrolizumab is a checkpoint inhibitor approved for the treatment of MSI-H/dMMR mCRC, and the BRAF inhibitor encorafenib, in combination with cetuximab, is approved for previously treated BRAF V600E-mutant mCRC. Combination of pembrolizumab with encorafenib and cetuximab may synergistically enhance antitumor activity in patients with BRAF V600E-mutant, MSI-H/dMMR mCRC. SEAMARK is a randomized phase II study comparing the efficacy of the combination of pembrolizumab with encorafenib and cetuximab versus pembrolizumab alone in patients with previously untreated BRAF V600E-mutant, MSI-H/dMMR mCRC.
publishDate 2024
dc.date.none.fl_str_mv 2
2024-01-01
2024
2024-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/326606
https://dx.doi.org/urn:doi:10.2217/fon-2022-1249
url https://ddd.uab.cat/record/326606
https://dx.doi.org/urn:doi:10.2217/fon-2022-1249
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410145496203264
score 15,81155

Similar Items